RecruitingPhase 1NCT06545942

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Sponsor

MOMA Therapeutics

Enrollment

220 participants

Start Date

Aug 13, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Ovarian Cancer Prostate Cancer Advanced Solid Tumor Metastatic Solid Tumor Pancreas Cancer Homologous Recombination Deficiency

Summary

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing an oral drug called MOMA-313 in people with advanced solid tumors — either alone or in combination with olaparib — particularly for tumors that have defects in DNA repair (called homologous recombination deficiency or HR deficiency). **You may be eligible if...** - You are 18 or older with a confirmed advanced, relapsed, or metastatic solid tumor that cannot be cured with current treatments - Your tumor has a known HR-deficiency alteration (a specific type of DNA repair defect) - For the combination arm: your cancer is one for which a PARP inhibitor would be appropriate, such as prostate cancer or pancreatic cancer **You may NOT be eligible if...** - Your tumor does not have an HR-deficient alteration - You have poor organ function or performance status - You have active brain metastases or serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMOMA-313

MOMA-313 administered orally

DRUGOlaparib

Olaparib administered orally

Locations(18)

Investigative Site #108

Goodyear, Arizona, United States

Investigative Site #101

La Jolla, California, United States

Investigative Site #111

San Francisco, California, United States

Investigative Site #104

Lake Mary, Florida, United States

Investigative Site #110

St Louis, Missouri, United States

Investigative Site #103

New York, New York, United States

Investigative Site #106

New York, New York, United States

Investigative Site #109

Philadelphia, Pennsylvania, United States

Investigative Site #107

Myrtle Beach, South Carolina, United States

Investigative Site #102

Nashville, Tennessee, United States

Investigative Site #105

San Antonio, Texas, United States

Investigative Site #112

Fairfax, Virginia, United States

Investigative Site #114

Barcelona, Spain

Investigative Site #116

Barcelona, Spain

Investigative Site #115

Madrid, Spain

Investigative Site #113

London, United Kingdom

Investigative Site #117

Manchester, United Kingdom

Investigative Site #118

Newcastle upon Tyne, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06545942

Related Trials

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT0731855828 locations

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT0700515433 locations

Genomic Services Research Program

NCT025959571 location

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT068073593 locations

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT0733644618 locations